Company Profile

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc., develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care. Its product, the TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor's office. The TearLab Osmolarity System consists of approximately three components: the TearLab disposable, the TearLab Pen, and the TearLab Reader. The TearLab disposable is a single-use microfluidic microchip. The TearLab Pen is a hand-held device that interfaces with the TearLab disposable. The TearLab Reader is a small desktop unit that allows for the docking of the TearLab Pen.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

23/24/23	Bausch + Lomb Corporation acquired TearLab Corporation from Accelmed Partners and other shareholders for approximately $24 million.	CI
09/21/09	TearLab Corporation Announces Board Appointments	CI

23/24/23	Bausch + Lomb Corporation acquired TearLab Corporation from Accelmed Partners and other shareholders for approximately $24 million.	CI
09/21/09	TearLab Corporation Announces Board Appointments	CI
09/21/09	TearLab Corporation Appoints Adam Szaronos as Chief Executive Officer	CI
09/21/09	Tearlab Corporation Appoints James V. Mazzo to the Company's Board of Directors	CI
16/21/16	MellingMedical and TearLab Agreement Aims to Enhance Early Detection of Dry Eye Disease in American Veterans	CI
29/20/29	TearLab Appoints Adam Szaronos as Chief Commercial Officer	CI
09/20/09	Accelmed Partners II, fund managed by Accelmed Fund (Accelmed Partners) completed the acquisition of TearLab Corporation.	CI
09/20/09	TearLab Corporation to Seek Acquisitions	CI
26/20/26	Tearlab Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020	CI
11/20/11	TearLab Corporation Announces Board Appointments	CI
11/20/11	Tearlab Mulls Inorganic Growth Opportunities	CI
11/20/11	TearLab Corporation announced that it expects to receive $25 million in funding from Accelmed Fund	CI
11/20/11	Accelmed Partners II, fund managed by Accelmed Fund (Accelmed Partners) entered into term sheet to acquire TearLab Corporation for $0.74 million.	CI

09/20/09	TEARLAB CORP : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
27/20/27	TearLab: 1Q Earnings Snapshot	AQ
26/20/26	TEARLAB : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	AQ
09/20/09	TEARLAB : Entry into a Material Definitive Agreement (form 8-K/A)	AQ
30/20/30	TEARLAB CORP : Entry into a Material Definitive Agreement (form 8-K)	AQ

Manager	Title	Age	Since
Adam Szaronos CEO	Chief Executive Officer	-	01/04/2026
Benjamin D. Sullivan CTO	Chief Tech/Sci/R&D Officer	-	17/07/2009
John Lund DFI	Director of Finance/CFO	60	01/07/2022

Director	Title	Age	Since
Uri Geiger BRD	Director/Board Member	58	09/07/2020
James V. Mazzo CHM	Chairman	68	09/12/2021
Richard Lindstrom BRD	Director/Board Member	78	01/09/2004

TearLab Corp Share Price OTC Bulletin Board

Stocks

Medical Equipment, Supplies & Distribution

Latest news : TearLab Corp

Press Releases: TearLab Corp

Managers and Directors: TearLab Corp

Glasses, Spectacles & Contact Lenses

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ESSILORLUXOTTICA	-0.71%	-2.01%	-40.34%	-7.72%	8.67TCr
ALCON INC.	+0.58%	-1.82%	-9.53%	-19.55%	3.55TCr
THE COOPER COMPANIES, INC.	-0.55%	+0.93%	+0.77%	-18.01%	1.48TCr
LENSKART SOLUTIONS LIMITED	-0.58%	+4.38%	-	-	1.2TCr
SHANGHAI CONANT OPTICAL CO., LTD.	+9.66%	+10.58%	-9.90%	+749.91%	253.27Cr
AUTEK CHINA INC.	-2.64%	-6.71%	-44.74%	-59.11%	142.62Cr
PEGAVISION CORPORATION	-1.61%	+0.69%	+15.64%	+8.44%	88Cr
MENICON CO., LTD.	-0.26%	-3.24%	+52.72%	-8.02%	89Cr
SPYGLASS PHARMA, INC.	-0.94%	+1.86%	-	-	88Cr
Average	+0.33%	+0.68%	-5.05%	+92.28%	1.73TCr
Weighted average by Cap.	-0.23%	+1.31%	-26.99%	+1.29%

End-of-day quote OTC Bulletin Board
- ^USD	-